Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutional guidelines * Agreement to allow the use of archival tissue from diagnostic tumor biopsies * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) 0 or 1 * Lung non-small cell carcinoma (NSCLC) patients with advanced, metastatic, or recurrent disease, previously treated with a PD-1 or PD-L1 immune checkpoint inhibitor, either as single agent or in combination with chemotherapy or other immunotherapy or experimental agents * Radiographically demonstrable tumor progression treatment on or after therapy with a PD-1/PD-L1 immune checkpoint inhibitor * Preserved organ function and recovery of prior drug related toxicities (except alopecia or grade 2 anemia) to grade 1 or better * No cytotoxic chemotherapy or immunotherapy over the three weeks prior to lymphodepletion * Histologically confirmed non-small cell lung cancer * Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 * Fully recovered from the acute toxic effects (except alopecia) to =\< grade 1 to prior anti-cancer therapy * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Hemoglobin (Hgb) \>= 8 g/dl * Platelets \>= 100,000/mm\^3 * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) =\< 1.5 x ULN * Alanine aminotransferase (ALT) =\< 1.5 x ULN * Alkaline phosphatase (…